Correspondence 0001193125-26-149595 from Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc.
Date: April 9, 2026 · CIK: 0001754068 · Accession: 0001193125-26-149595
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294881
Letter
Re: Kalaris Therapeutics, Inc. Registration Statement on Form S-3 Filed April 3, 2026 File No. 333-294881 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kalaris Therapeutics, Inc. (the “ Registrant ”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-294881), so that it may become effective at 4:00 p.m., Eastern Time, on April 13, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the U.S. Securities and Exchange Commission.
April 9, 2026 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549
Attention: Chris Edwards
Very truly yours,
Kalaris Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 9, 2026 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Chris Edwards Re: Kalaris Therapeutics, Inc. Registration Statement on Form S-3 Filed April 3, 2026 File No. 333-294881 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kalaris Therapeutics, Inc. (the “ Registrant ”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-294881), so that it may become effective at 4:00 p.m., Eastern Time, on April 13, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the U.S. Securities and Exchange Commission. Very truly yours, Kalaris Therapeutics, Inc. By: /s/ Andrew Oxtoby Name: Andrew Oxtoby Title: President and Chief Executive Officer